后世代氟喹诺酮使用与疑似耐药结核患者死亡率的关系
本研究为在印度、摩尔多瓦和南非开展的前瞻性队列研究,纳入834例结核分枝杆菌感染患者,评估后世代氟喹诺酮(莫西沙星或左氧氟沙星)使用与患者死亡率的关系。
要点
- 后世代氟喹诺酮使用与疑似耐药结核患者死亡风险降低相关。
- 因早世代氟喹诺酮耐药而从方案中移除后世代氟喹诺酮可能增加死亡风险。
核心结论
- 后世代氟喹诺酮使用显著降低本队列患者死亡风险。
- 因早世代氟喹诺酮耐药而移除后世代氟喹诺酮可能增加死亡风险。
研究设计与样本
- 前瞻性队列研究,作为比较诊断研究的一部分。
- 纳入印度、摩尔多瓦和南非耐药结核高流行医院和诊所的834例结核分枝杆菌感染患者。
- 使用Cox比例风险回归模型评估后世代氟喹诺酮使用与死亡率的关联。
临床怎么用
- 在疑似耐药结核患者中,后世代氟喹诺酮使用与较低死亡风险相关,支持其临床使用。
- 因早世代氟喹诺酮耐药而移除后世代氟喹诺酮可能增加死亡风险,需谨慎评估。
局限性
- 需进一步研究评估后世代氟喹诺酮对早世代氟喹诺酮耐药与敏感患者的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous retrospective and in vitro studies suggest that use of later-generation fluoroquinolones may reduce mortality risk and improve treatment outcomes for drug-resistant tuberculosis (TB) patients, including individuals resistant to a fluoroquinolone. Meta-analysis results are mixed and few studies have examined this relationship prospectively. METHODS: As part of a comparative diagnostic study, we conducted a prospective cohort study with 834 Mycobacterium tuberculosis-infected patients from selected hospitals and clinics with high prevalence of drug-resistant TB in India, Moldova, and South Africa. We used Cox proportional hazards regression models to assess the association between later-generation fluoroquinolone (moxifloxacin or levofloxacin) use and patient mortality, adjusting for risk factors typically associated with poor treatment outcomes. RESULTS: After adjusting for phenotypic resistance profile, low body mass index (<18.5 kg/m2), human immunodeficiency virus status, and study site, participants treated with a later-generation fluoroquinolone had half the risk of mortality compared with participants either not treated with any fluoroquinolone or treated only with an earlier-generation fluoroquinolone (adjusted hazard ratio, 0.46 [95% confidence interval, .26-.80]) during follow-up. CONCLUSIONS: Use of later-generation fluoroquinolones significantly reduced patient mortality risk in our cohort, suggesting that removal of a later-generation fluoroquinolone from a treatment regimen because of demonstrated resistance to an earlier-generation fluoroquinolone might increase mortality risk. Further studies should evaluate the effectiveness of later-generation fluoroquinolones among patients with and without resistance to early-generation fluoroquinolones. CLINICAL TRIALS REGISTRATION: NCT02170441.
引用
- Seifert M, Georghiou SB, Garfein RS, et al. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clin Infect Dis. 2017. PMID: 28475735. doi:10.1093/cid/cix422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。